Senores Pharmaceuticals, through its wholly-owned US subsidiary, has signed an agreement to acquire the US FDA-approved Abbreviated New Drug Application (ANDA) for enalapril maleate tablets from Wockhardt. The acquisition covers all four dosage strengths: 2.5mg, 5mg, 10mg, and 20mg.
Enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor, is indicated for the treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. The medication works by relaxing blood vessels, allowing blood to flow more easily and reducing the workload on the heart.
Market Opportunity
According to IQVIA data, the US market for enalapril tablets was valued at $28.60 million (MAT December 2024). Alternative market analysis from Symphony, a specialty data aggregator, places the market value even higher at $109.24 million (MAT March 2025), highlighting the significant commercial potential of this acquisition.
This strategic move aligns with Senores' ongoing expansion in the US generic pharmaceutical market, where pricing pressures and competition have intensified in recent years.
Expanding US Portfolio
The acquisition bolsters Senores' growing presence in the US pharmaceutical market. The company's current portfolio now includes 61 ANDAs and 22 Contract Manufacturing Organization/Contract Development and Manufacturing Organization (CMO/CDMO) commercial products approved for distribution in the United States.
"This acquisition represents another step in our strategy to build a diverse portfolio of essential medications for the US market," said a company representative. "Enalapril is a well-established treatment option for cardiovascular conditions that affect millions of Americans."
Global Manufacturing Capabilities
Beyond the US market, Senores has established itself as a manufacturer of complex generics certified by global regulatory authorities. The company delivers generic drugs to emerging markets across more than 40 countries worldwide.
Senores' manufacturing facility in Chhatral has received regulatory approvals from authorities in more than 10 countries for emerging markets. The company currently holds over 280 product registrations globally, with an additional 630 product applications in various stages of approval.
The facility's capabilities extend beyond oral solid dosage forms to include critical care injectables and active pharmaceutical ingredients (APIs), demonstrating Senores' vertical integration strategy.
Cardiovascular Focus
The addition of enalapril maleate tablets strengthens Senores' position in the cardiovascular therapeutic area, one of the largest pharmaceutical markets globally. Hypertension affects approximately 116 million adults in the United States alone, according to the Centers for Disease Control and Prevention.
ACE inhibitors like enalapril remain a cornerstone of hypertension management, particularly for patients with comorbid conditions such as heart failure, diabetes, or kidney disease. The medication's established safety profile and efficacy make it a preferred option for many healthcare providers.
Future Growth Strategy
This transaction represents the latest in Senores' strategic acquisitions aimed at expanding its product portfolio and geographic reach. The company continues to focus on both organic growth through internal product development and inorganic growth through targeted acquisitions.
Industry analysts note that acquiring approved ANDAs provides pharmaceutical companies with a faster path to market compared to developing products from scratch, which can take years and involve significant regulatory hurdles.
As Senores continues to expand its global footprint, the company appears positioned to leverage its manufacturing capabilities and growing product portfolio to compete effectively in both established and emerging pharmaceutical markets.
